Kazia Therapeutics Ltd · NASDAQ:KZIA
Kazia Therapeutics — Corporate Update (June 2023)
43 slides from Kazia Therapeutics's corporate update, Jun 26, 2023
Slide 1: Kazia Corporate Update and Corporate Presentation
ASX ANNOUNCEMENT 26 June 2023 KAZIA CORPORATE UPDATE AND CORPORATE PRESENTATION Sydney, 26 June 2023 – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology- focused drug development company, is pleased to provide an update on key corporate and clinical initiatives and release a new inves
Slide 2: Clinical programs update
Clinical programs update 11 clinical trials are currently in progress or in planning for Kazia’s two assets, paxalisib and EVT-801, and Kazia continues to execute across all programs. Current program highlights are set out in brief below. Refer to the appended corporate presentation for more detail:
Slide 3: MSKCC phase I clinical study; EVT-801
MSKCC phase I clinical study Paxalisib is the subject of an ongoing phase I clinical study in combination with radiotherapy for the treatment of brain metastases, sponsored by Memorial Sloan Kettering Cancer Center in New York, NY. Kazia is pleased to confirm that the phase I expansion cohort is enr
Slide 4: Forward-Looking Statements
tumour types and has shown evidence of synergy with immuno-oncology agents. A phase I study commenced recruitment in November 2021. For more information, please visit www.kaziatherapeutics.com or follow us on Twitter @KaziaTx. This document was authorized for release to the ASX by John Friend, Chief
Slide 5: A Diversified Oncology Drug Development Company
A Diversified Oncology Drug Development Company June 2023 ASX: KZA | NASDAQ: KZIA | Twitter: @KaziaTx
Slide 6: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, which can generally be identified as such by the use of words such as “may,” “will,” “estimate,” “future,” “forward,” “anticipate,” “plan,” “expect,” “explore,” “potential” or other similar words. Any statement describ
Slide 7: Company Overview
Company Overview A late-clinical-stage oncology drug development company Paxalisib EVT801 Company is dual-listed on NASDAQ (KZIA) and ASX (KZA) with market cap around US$ 27 million Brain-penetrant pan-PI3K / mTOR inhibitor Selective VEGFR3 inhibitor • Well-validated class with five FDA-approved the
Slide 8: Pipeline – Two Differentiated Assets
Pipeline – Two Differentiated Assets Lead asset provides a ‘pipeline in a molecule’ Paxalisib licensed from: Investigational, small molecule, potent, brain-penetrant inhibitor of PI3K / mTOR Preclinical PHASE 1 PHASE 2 PHASE 3 MARKET Anticipated Glioblastoma & IDH-mutant glioma Final Data 3 studies
Slide 9: Paxalisib History
Paxalisib History Asset licensed from Genentech in 2016 Kazia commences phase I clinical Kazia commences phase II Positive final data from phase II trial in diffuse midline glioma clinical trials in brain metastases glioblastoma study • Partnership with St Jude • Partnerships with leading US • Basis
Slide 10: CY2023 Milestones and Newsflow
CY2023 Milestones and Newsflow Multiple catalysts across two clinical programs Preclinical data for paxalisib in melanoma presented at AACR (2023) 1H CY2023 Preclinical data for paxalisib in DMG/DIPG & AT/RT presented at AACR (2023) 1H CY2023 Preliminary data from Kazia’s EVT801 phase I trial pr
Slide 11: Paxalisib Mechanism of Action
Paxalisib Mechanism of Action Only brain-penetrant drug in development within the PI3K inhibitor class 1 The PI3K pathway is activated in 2 Five PI3K inhibitors have already 3 Paxalisib is the only brain- many forms of cancer been approved by FDA penetrant PI3K inhibitor • Chronic lymphocytic Only 2
Slide 12: Glioblastoma
Glioblastoma 7
Slide 13: Paxalisib in Glioblastoma: High unmet need
Paxalisib in Glioblastoma High unmet need, especially in ‘MGMT unmethylated’ patients Standard of Care Debulking surgery Radiotherapy + Temozolomide (‘Stupp where possible temozolomide maintenance therapy Regimen’) 6 weeks 4w 6 x 28-day cycles Methylated MGMT Status ~35% of patients respond to temoz
Slide 14: Phase II study PFS and OS in glioblastoma
Paxalisib in Glioblastoma Phase II study suggests encouraging PFS and OS in context of current treatment landscape Progression-Free Survival (PFS) Overall Survival (OS) (n=30) (n=30) Median PFS: 8.6 months (6.6-11.0) Median OS: 15.7 months (11.1-19.1) Comparator figure for existing therapy: 5.3 mont
Slide 15: Safety profile in Phase II study
Paxalisib in Glioblastoma Safety profile in Phase II study is favorable for a drug in advanced cancer Number of Patients at Any Dose (n=30) Experiencing AEs ‘Possibly’ or ‘Likely’ Related to Paxalisib (affecting ≥10% of patients) Term Gr 1 Gr 2 Gr 3 Gr 4 Total (%) Fatigue 3 13 2 18 (60%) Stomatitis
Slide 16: Adaptive multi-drug study GBM AGILE is ongoing
Paxalisib in Glioblastoma Adaptive multi-drug study, GBM AGILE, is ongoing Key Points Completed Regorafenib Negative outcome • A ‘platform study’, sponsored by Bayer (Sep 22) GCAR run independently of individual Paxalisib 3 Ongoing companies, designed to expedite the Kazia Therapeutics Economies of
Slide 17: GBM AGILE interim analysis may have been premature
Paxalisib in Glioblastoma We believe GBM AGILE’s interim analysis may have been premature OVERALL STUDY DESIGN up to 150 patients 50 patients Stage 1 (‘Exploratory’) Stage 2 (‘Confirmatory’) Full FDA Approval Blinded Graduation Analysis POTENTIAL CONTRIBUTORY FACTORS TO PAXALISIB GRADUATION RESULT 1
Slide 18: Cornell study of low-insulin state
Paxalisib in Glioblastoma Cornell study to investigate if low-insulin state enhances paxalisib activity OVERALL STUDY DESIGN Rationale of conducting the study • As with most PI3K inhibitors, Newly-diagnosed GBM hyperglycemia is a key toxicity (unmethylated MGMT) Ongoing Paxalisib + metformin Study a
Slide 19: LUMOS2 Clinical Study in IDH-Mutant Glioma
Paxalisib in Grade 2/3 IDH-Mutant Glioma LUMOS 2 Clinical Study • LUMOS2 is a prospective, multi-center, open-label, multi-arm, phase II, biomarker-directed, signal-seeking, umbrella clinical trial sponsored by University of Sydney – Adults with progressive grade 2/3, IDH-mutant glioma at recurrence
Slide 20: Childhood brain cancers
Childhood brain cancers 15
Slide 21: Summary of Paxalisib in Childhood Brain Cancer
Summary of Paxalisib in Childhood Brain Cancer Kazia has interest in at least three forms of childhood brain cancer Diffuse Midline Gliomas (DMG, Atypical Teratoid / Advanced Childhood Cancer DIPG) Rhabdoid Tumors (AT/RT) (PI3K/mTOR activated) Positive preclinical data in combination Positive precli
Slide 22: Childhood Brain Cancer: High unmet need
Paxalisib in Childhood Brain Cancer High unmet need especially in patients with diffuse midline gliomas (DMGs) 1 Brain cancer is the most common 2 Brain cancer represents about one third 3 Prognosis of childhood brain cancer, malignancy of childhood of childhood cancer deaths especially DMGs, has im
Slide 23: Phase I trial in Diffuse Midline Gliomas
Paxalisib in Diffuse Midline Gliomas Phase I trial (St. Jude Children study) showed paxalisib was generally well tolerated in children OVERALL STUDY DESIGN Results from Phase I trial MTD of paxalisib has been established Newly diagnosed H3K27-mutant Newly-diagnosed DIPG DMG Paxalisib exhibited a
Slide 24: ONC201 and paxalisib synergistic in preclinical model
Paxalisib in Diffuse Midline Gliomas Combination of ONC201 and paxalisib appeared synergistic in preclinical model The in vivo xenograft model demonstrated extended Addition of paxalisib rescued ONC201 from pAKT survival with the addition of paxalisib activation Source: Jackson, et al. ONC201 in com
Slide 25: Multi-arm study PNOC022 is underway
Paxalisib in Diffuse Midline Gliomas Multi-arm, global site study, PNOC022, is underway OVERALL STUDY DESIGN Single agent in target validation Combination therapy in Three different cohorts and/or radiation phase maintenance phase TV: ONC201 Day -1 ONC201 once weekly + paxalisib Newly-diagnosed DMG
Slide 26: Case studies from compassionate use
Paxalisib in Diffuse Midline Gliomas Case studies from compassionate use suggest activity Patient 1 Patient 2 • Commenced ONC201 + paxalisib immediately • Commenced ONC201 + paxalisib following following re-irradiation radiotherapy after diagnosis • At 5 months, MRI showed continued regression of •
Slide 27: Australian phase II study OPTIMISE
Paxalisib in Childhood Brain Cancer Australian phase II study, OPTIMISE, anticipated enrollment in 2H 2023 The trial explores paxalisib in combination with existing chemotherapy agents for the treatment of children with high-risk malignancies, including (but not confined to) brain tumors 18 patients
Slide 28: Atypical Teratoid / Rhabdoid Tumor: monotherapy activity
Paxalisib in Atypical Teratoid / Rhabdoid Tumor Monotherapy showed activity in vivo models Paxalisib monotherapy slowed tumor growth and extended survival High unmet need in mice bearing AT/RT orthotopic xenograft tumors • Atypical Teratoid /Rhabdoid Tumors (AT/RT) are the most common malignant brai
Slide 29: Brain metastases
Brain metastases 24
Slide 30: Summary of Brain Metastases Clinical Studies Underway
Summary of Brain Metastases Clinical Studies Underway Registration Indication Phase N Status Sponsor Secondary (Metastatic) Brain Cancer Brain Metastases NCT04192981 I Up to 36 Recruiting (combination with radiotherapy) Breast Cancer Brain Metastases NCT03765983 II Up to 47 Recruiting (combination w
Slide 31: PI3K pathway mutations in brain metastasis
Paxalisib in Brain Metastasis PI3K pathway mutations are common in brain metastases and associated with a worse prognosis No Yes PIK3CA mutation Yes No CNS failure after WBRT CNS failure after SRS +PIK3CA mutations at 1 yr –PIK3CA mutations at 1 yr CNS failure after 48 (26-67) 30 (21-40) WBRT, % (95
Slide 32: Phase I interim analysis in brain metastasis
Paxalisib in Brain Metastasis Phase I trial’s interim analysis showed encouraging clinical activity of paxalisib in combination with radiation therapy OVERALL STUDY DESIGN 12 patients enrolled (9 evaluable, 3 did not complete protocol treatment) Additional 12 patients Stage 1 (‘Exploratory’) Stage 2
Slide 33: Phase II trial with trastuzumab in BCBM
Paxalisib in Brain Metastasis Phase II trial to evaluate efficacy with trastuzumab in BCBM patients OVERALL STUDY DESIGN Rationale of conducting the study • The PI3K/Akt/mTOR is an Cohort A: Single-arm, two-stage important pathway in HER2- (~37 patients) positive breast cancer brain Ongoing Treatmen
Slide 34: Genomically guided phase II study in brain metastases
Paxalisib in Brain Metastasis Genomically guided phase II study of multiple therapies in patients with brain metastases Depending on genetic mutation of cancer Rationale of conducting the study Abemaciclib • Approximately 30% of patients Eli Lilly Completed Breast cancer with metastatic cancer devel
Slide 35: Primary CNS lymphoma
Primary CNS lymphoma 30
Slide 36: Phase II trial in Primary CNS lymphoma
Paxalisib in Primary CNS lymphoma Phase II trial to evaluate safety and efficacy of paxalisib in PCNSL Preliminary results anticipated 2H23 OVERALL STUDY DESIGN Rationale of conducting the study • PCNSL is a subtype of lymphoma Ongoing 25 patients with recurrent Treatment: paxalisib that exclusively
Slide 37: Other solid tumors
Other solid tumors 32
Slide 38: Paxalisib in Metastatic Melanoma: in vivo activity
Paxalisib in Metastatic Melanoma Paxalisib showed potent single agent activity in an in vivo melanoma model Tumor Volume (Activity) Animal Weight (Tolerability) Survival (Efficacy) Source: AACR 2023 abstracts 33
Slide 39: Paxalisib in refractory melanoma
Paxalisib in Metastatic Melanoma Paxalisib showed potential as therapeutic strategy in refractory melanoma Paxalisib blocked proliferation in vitro (cell confluence assay) Unmet need • Melanoma is the 5th most common cancer for men & women in the U.S. • Approximately 50% of all melanomas harbor an a
Slide 40: Paxalisib – Potential Paths to Registration
Paxalisib – Potential Paths to Registration Multiple opportunities to become a marketed product Diffuse Midline Gliomas Initial data from • Potential path to accelerated approval via phase II study ongoing phase II study with ONC201 • Existing Rare Pediatric Disease Designation 3Q CY2023 creates pos
Slide 41: Second Drug in Clinical Trials: EVT801
Second Drug in Clinical Trials EVT801 has potential in a wide range of cancers Explore EVT801 as Future Phase II Future Pivotal an anti-angiogenic Study Study therapy, likely in tumours that Monotherapy Monotherapy ONGOING express high VEGFR3 One or more solid One or more solid Phase I Study tumours
Slide 42: Board and Management Team
Board and Management Team Extensive experience in drug development Board of Directors Management Team Scientific Advisory Board Iain Ross Dr John Friend Priscilla Brastianos, MD Chairman of the Board Chief Executive Officer Bryce Carmine Karen Krumeich John de Groot, MD Independent Director Chief Fi
Slide 43: www.kaziatherapeutics.com
www.kaziatherapeutics.com info@kaziatherapeutics.com